| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7198801 | ALLERGAN | Formulations for transdermal or transmucosal application |
Jun, 2022
(1 year, 3 months ago) | |
Gelnique 3% is owned by Allergan.
Gelnique 3% contains Oxybutynin.
Gelnique 3% has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Gelnique 3% are:
- US7198801
Gelnique 3% was authorised for market use on 07 December, 2011.
Gelnique 3% is available in gel, metered;transdermal dosage forms.
The generics of Gelnique 3% are possible to be released after 25 June, 2022.
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 07 December, 2011
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
More Information on Dosage
GELNIQUE 3% family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic